Señales en vivo de KYMR | Maximiza tus Ganancias con Getagraph.com

COMPRAR 115044 min ago

@ $36.93

Emitido: 14 feb 2024 @ 15:32

Retorno: 1.27%

Señal anterior: feb 14 - 09:30

Señal anterior: Vender

Retorno: 3.50 %

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Stats
Volumen de hoy	529 366
Volumen promedio	639 964
Capitalización de mercado	2.29B
EPS	$0 ( 2024-05-02 )
Próxima fecha de ganancias	( $-0.730 ) 2024-06-18
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.84
ATR14	$0.0450 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Baker Bros. Advisors Lp	Buy	32 000	Non-Qualified Stock Option (right to buy)
2024-03-28	Baker Bros. Advisors Lp	Buy	0	Common Stock
2024-03-28	Baker Bros. Advisors Lp	Buy	0	Common Stock
2024-03-28	Baker Bros. Advisors Lp	Buy	7 379 066	Prefunded Warrants
2024-03-14	Booth Bruce	Sell	34 473	Common Stock

INSIDER POWER
44.21
Last 97 transactions
Buy: 2 823 290 \| Sell: 1 008 904

Volumen Correlación

Largo: 0.15 (neutral)

Corto: 0.37 (neutral)

Signal:(59.897) Neutral

Kymera Therapeutics, Inc. Correlación

10 Correlaciones Más Positivas
MRUS	0.941
SLN	0.938
SWTX	0.937
YMAB	0.936
IMNM	0.935
TNYA	0.933
SRTS	0.93
EOLS	0.927
REYN	0.923
FWRG	0.922

10 Correlaciones Más Negativas
RTPY	-0.94
VALN	-0.934
RELL	-0.921
BFRI	-0.907
DSWL	-0.907
CNTY	-0.905
CRCT	-0.902
BSGM	-0.899
KVSB	-0.897
SVOK	-0.897

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kymera Therapeutics, Inc. Correlación - Moneda/Commodity

0.00
( neutral )

-0.17
( neutral )

0.00
( neutral )

0.16
( neutral )

-0.51
( weak negative )

-0.52
( weak negative )

Kymera Therapeutics, Inc. Finanzas

Annual	2023
Ingresos:	$78.59M
Beneficio Bruto:	$75.03M (95.46 %)
EPS:	$-2.52

FY	2023
Ingresos:	$78.59M
Beneficio Bruto:	$75.03M (95.46 %)
EPS:	$-2.52

FY	2022
Ingresos:	$46.83M
Beneficio Bruto:	$43.85M (93.64 %)
EPS:	$-2.82

FY	2021
Ingresos:	$72.83M
Beneficio Bruto:	$72.83M (100.00 %)
EPS:	$-1.976

Financial Reports:

No articles found.

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.